Spotlight on Cardiology

Karol E. Watson, MD, PhD, FACC, FAHA
Credits: 1.25 CME
Addressing Disparities in Care: Focus on Hyperlipidemia – In Case You Missed the American College of Cardiology Meeting
Karol E. Watson, MD, PhD, FACC, FAHA
Vindico Medical Education

Addressing Disparities in Care: Focus on Hyperlipidemia – In Case You Missed the American College of Cardiology Meeting

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Educational Partner:

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the impact of gender and race on CVD screening, management, and outcomes.
  • Assess the latest data regarding the impact of oral, non-statin therapies on LDL-C and how they may benefit women and/or minority populations.
  • Assess the latest recommendations regarding triglyceride-lowering therapies that confer benefit on CV outcomes for patients with atherosclerotic CVD.

Activity Description

In the United States, cardiovascular disease (CVD) is the leading cause of death, claiming more than 800,000 lives annually. Prevalence of CVD is increasing disproportionately in Black and Hispanic populations as well as in women. Dyslipidemia is a major risk factor for adverse CV outcomes, with 30% of US adults having elevated LDL-C (≥130 mg/dL). Similarly, as many as 22% of adults have high triglyceride levels, according to data from 2013-2016. While many patients with elevated LDL-C and triglyceride levels benefit from statin therapy, about 10% to 30% experience statin intolerance or dose-limiting toxicities, leaving them at risk for adverse CV events. Add-on medications may further reduce LDL-C and triglyceride levels for these patients. In this continuing education activity, expert clinicians discuss how to manage patients with elevated LDL-C and hypertriglyceridemia as well as provide strategies to address the racial and gender disparities observed in the care of patients with CVD.

Agenda

Introduction - Karol E. Watson, MD, PhD, FACC, FAHA
Racial and Gender Disparities in CVD - Karol E. Watson, MD, PhD, FACC, FAHA
Advances in LDL-C Reduction: Implications for Treatment and Safety - Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Residual Cardiovascular Risk Reduction - Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Clinical Cases - Moderated by Karol E. Watson, MD, PhD, FACC, FAHA

Activity Chair

Karol E. Watson, MD, PhD, FACC, FAHA
Professor of Medicine/Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Co-Director, UCLA Program in Preventive Cardiology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

Faculty

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
Member
Louisiana Governor’s COVID-19 Health Equity Task Force
Louisiana Vaccine Action Collaborative (VAC)
New Orleans, LA

Disclosure: Consulting Fee: Alnylam, Amgen, Medtronic, Novartis


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC

Disclosure: Consulting Fee: Amgen, Esperion, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education and Association of Black Cardiologists Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Amarin Pharma Inc. and Esperion Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Association of Black Cardiologists continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and Association of Black Cardiologists. Neither Vindico Medical Education, Association of Black Cardiologists nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Educational Partner:

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the impact of gender and race on CVD screening, management, and outcomes.
  • Assess the latest data regarding the impact of oral, non-statin therapies on LDL-C and how they may benefit women and/or minority populations.
  • Assess the latest recommendations regarding triglyceride-lowering therapies that confer benefit on CV outcomes for patients with atherosclerotic CVD.

Activity Description

In the United States, cardiovascular disease (CVD) is the leading cause of death, claiming more than 800,000 lives annually. Prevalence of CVD is increasing disproportionately in Black and Hispanic populations as well as in women. Dyslipidemia is a major risk factor for adverse CV outcomes, with 30% of US adults having elevated LDL-C (≥130 mg/dL). Similarly, as many as 22% of adults have high triglyceride levels, according to data from 2013-2016. While many patients with elevated LDL-C and triglyceride levels benefit from statin therapy, about 10% to 30% experience statin intolerance or dose-limiting toxicities, leaving them at risk for adverse CV events. Add-on medications may further reduce LDL-C and triglyceride levels for these patients. In this continuing education activity, expert clinicians discuss how to manage patients with elevated LDL-C and hypertriglyceridemia as well as provide strategies to address the racial and gender disparities observed in the care of patients with CVD.

Agenda

Introduction - Karol E. Watson, MD, PhD, FACC, FAHA
Racial and Gender Disparities in CVD - Karol E. Watson, MD, PhD, FACC, FAHA
Advances in LDL-C Reduction: Implications for Treatment and Safety - Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Residual Cardiovascular Risk Reduction - Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Clinical Cases - Moderated by Karol E. Watson, MD, PhD, FACC, FAHA

Activity Chair

Karol E. Watson, MD, PhD, FACC, FAHA
Professor of Medicine/Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Co-Director, UCLA Program in Preventive Cardiology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

Faculty

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
Member
Louisiana Governor’s COVID-19 Health Equity Task Force
Louisiana Vaccine Action Collaborative (VAC)
New Orleans, LA

Disclosure: Consulting Fee: Alnylam, Amgen, Medtronic, Novartis


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC

Disclosure: Consulting Fee: Amgen, Esperion, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education and Association of Black Cardiologists Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Amarin Pharma Inc. and Esperion Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Association of Black Cardiologists continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and Association of Black Cardiologists. Neither Vindico Medical Education, Association of Black Cardiologists nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Cardiology Presentations

James E. Udelson, MD, FAHA
American Heart Association
Hypertrophic Cardiomyopathy for Professionals – Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis

Hypertrophic Cardiomyopathy for Professionals – Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis

Start

This educational activity has not been certified for Continuing Medical Education credit.

Released: January 4, 2022
Expires: January 4, 2023
60 minutes to complete

Provided By

Target Audience

Clinical general cardiology audience — physicians, nurses, nurse practitioners, physician assistants

Learning Objectives

  • Identify incidence and under-diagnosis of HCM in general population
  • Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  • Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  • Discuss alternative etiologies/diagnoses to be considered
  • Discuss how genetic testing can help differentiate between diagnoses
  • Review guideline-directed care, including appropriate referral to specialists

Activity Description

HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Watch this informative webinar today and improve patient outcomes.

Statement of Educational Need

Hypertrophic cardiomyopathy is a challenging disease to diagnose and often goes undiagnosed, putting patients at risk of sudden cardiac death, heart failure, and arrhythmias.

Agenda

  1. Discuss incidence and under-diagnosis of HCM in general population
  2. Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  3. Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  4. Discuss alternative etiologies/diagnoses to be considered
  5. Discuss how genetic testing can help differentiate between diagnoses
  6. Review guideline-directed care, including appropriate referral to specialists

Moderator

James E. Udelson, MD, FAHA
Chief, Division of Cardiology
Tufts Medical Center
Boston, MA

Presenters

Sharon Cresci, MD, FAHA, FACC, FASE
Cardiovascular Division Associate Professor of Medicine
Associate Professor of Genetics
Washington University
St. Louis, MO


Anjali Tiku Owens, MD
Director, Penn Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA


Matthew Martinez, MD, FACC
Director, Sports Cardiology
Co-Director, Chanin T Mast Hypertrophic Cardiomyopathy Center
Morristown, NJ

Disclosures

All persons who develop and/or control educational content in activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Moderator
James E. Udelson, MD, FAHA
Disclosure – None

Presenters
Sharon Cresci, MD, FAHA, FACC, FASE
Disclosure – None

Anjali Tiku Owens, MD
Disclosure – Myokardia (now Bristol Myers Squibb)

Matthew Martinez, MD, FACC
Disclosure – Bristol Myers Squibb

This represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire, which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Statement of Commercial Support

Bristol Myers Squibb is a national supporter of the American Heart Association’s hypertrophic cardiomyopathy initiative.

Contact Information for Questions About the Activity

Please contact Sheila.Jackson@heart.org with questions about this webinar.

This educational activity has not been certified for Continuing Medical Education credit.

Released: January 4, 2022
Expires: January 4, 2023
60 minutes to complete

Provided By

Target Audience

Clinical general cardiology audience — physicians, nurses, nurse practitioners, physician assistants

Learning Objectives

  • Identify incidence and under-diagnosis of HCM in general population
  • Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  • Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  • Discuss alternative etiologies/diagnoses to be considered
  • Discuss how genetic testing can help differentiate between diagnoses
  • Review guideline-directed care, including appropriate referral to specialists

Activity Description

HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Watch this informative webinar today and improve patient outcomes.

Statement of Educational Need

Hypertrophic cardiomyopathy is a challenging disease to diagnose and often goes undiagnosed, putting patients at risk of sudden cardiac death, heart failure, and arrhythmias.

Agenda

  1. Discuss incidence and under-diagnosis of HCM in general population
  2. Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  3. Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  4. Discuss alternative etiologies/diagnoses to be considered
  5. Discuss how genetic testing can help differentiate between diagnoses
  6. Review guideline-directed care, including appropriate referral to specialists

Moderator

James E. Udelson, MD, FAHA
Chief, Division of Cardiology
Tufts Medical Center
Boston, MA

Presenters

Sharon Cresci, MD, FAHA, FACC, FASE
Cardiovascular Division Associate Professor of Medicine
Associate Professor of Genetics
Washington University
St. Louis, MO


Anjali Tiku Owens, MD
Director, Penn Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA


Matthew Martinez, MD, FACC
Director, Sports Cardiology
Co-Director, Chanin T Mast Hypertrophic Cardiomyopathy Center
Morristown, NJ

Disclosures

All persons who develop and/or control educational content in activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Moderator
James E. Udelson, MD, FAHA
Disclosure – None

Presenters
Sharon Cresci, MD, FAHA, FACC, FASE
Disclosure – None

Anjali Tiku Owens, MD
Disclosure – Myokardia (now Bristol Myers Squibb)

Matthew Martinez, MD, FACC
Disclosure – Bristol Myers Squibb

This represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire, which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Statement of Commercial Support

Bristol Myers Squibb is a national supporter of the American Heart Association’s hypertrophic cardiomyopathy initiative.

Contact Information for Questions About the Activity

Please contact Sheila.Jackson@heart.org with questions about this webinar.

Bart Duell, MD
1.00 CME / MOC / CNE
American Heart Association
W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

Start

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Karol E. Watson, MD, PhD, FACC, FAHA
1.25 CME
Vindico Medical Education
Addressing Disparities in Care: Focus on Hyperlipidemia – In Case You Missed the American College of Cardiology Meeting

Addressing Disparities in Care: Focus on Hyperlipidemia – In Case You Missed the American College of Cardiology Meeting

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Educational Partner:

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the impact of gender and race on CVD screening, management, and outcomes.
  • Assess the latest data regarding the impact of oral, non-statin therapies on LDL-C and how they may benefit women and/or minority populations.
  • Assess the latest recommendations regarding triglyceride-lowering therapies that confer benefit on CV outcomes for patients with atherosclerotic CVD.

Activity Description

In the United States, cardiovascular disease (CVD) is the leading cause of death, claiming more than 800,000 lives annually. Prevalence of CVD is increasing disproportionately in Black and Hispanic populations as well as in women. Dyslipidemia is a major risk factor for adverse CV outcomes, with 30% of US adults having elevated LDL-C (≥130 mg/dL). Similarly, as many as 22% of adults have high triglyceride levels, according to data from 2013-2016. While many patients with elevated LDL-C and triglyceride levels benefit from statin therapy, about 10% to 30% experience statin intolerance or dose-limiting toxicities, leaving them at risk for adverse CV events. Add-on medications may further reduce LDL-C and triglyceride levels for these patients. In this continuing education activity, expert clinicians discuss how to manage patients with elevated LDL-C and hypertriglyceridemia as well as provide strategies to address the racial and gender disparities observed in the care of patients with CVD.

Agenda

Introduction - Karol E. Watson, MD, PhD, FACC, FAHA
Racial and Gender Disparities in CVD - Karol E. Watson, MD, PhD, FACC, FAHA
Advances in LDL-C Reduction: Implications for Treatment and Safety - Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Residual Cardiovascular Risk Reduction - Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Clinical Cases - Moderated by Karol E. Watson, MD, PhD, FACC, FAHA

Activity Chair

Karol E. Watson, MD, PhD, FACC, FAHA
Professor of Medicine/Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Co-Director, UCLA Program in Preventive Cardiology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

Faculty

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
Member
Louisiana Governor’s COVID-19 Health Equity Task Force
Louisiana Vaccine Action Collaborative (VAC)
New Orleans, LA

Disclosure: Consulting Fee: Alnylam, Amgen, Medtronic, Novartis


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC

Disclosure: Consulting Fee: Amgen, Esperion, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education and Association of Black Cardiologists Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Amarin Pharma Inc. and Esperion Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Association of Black Cardiologists continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and Association of Black Cardiologists. Neither Vindico Medical Education, Association of Black Cardiologists nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Educational Partner:

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the impact of gender and race on CVD screening, management, and outcomes.
  • Assess the latest data regarding the impact of oral, non-statin therapies on LDL-C and how they may benefit women and/or minority populations.
  • Assess the latest recommendations regarding triglyceride-lowering therapies that confer benefit on CV outcomes for patients with atherosclerotic CVD.

Activity Description

In the United States, cardiovascular disease (CVD) is the leading cause of death, claiming more than 800,000 lives annually. Prevalence of CVD is increasing disproportionately in Black and Hispanic populations as well as in women. Dyslipidemia is a major risk factor for adverse CV outcomes, with 30% of US adults having elevated LDL-C (≥130 mg/dL). Similarly, as many as 22% of adults have high triglyceride levels, according to data from 2013-2016. While many patients with elevated LDL-C and triglyceride levels benefit from statin therapy, about 10% to 30% experience statin intolerance or dose-limiting toxicities, leaving them at risk for adverse CV events. Add-on medications may further reduce LDL-C and triglyceride levels for these patients. In this continuing education activity, expert clinicians discuss how to manage patients with elevated LDL-C and hypertriglyceridemia as well as provide strategies to address the racial and gender disparities observed in the care of patients with CVD.

Agenda

Introduction - Karol E. Watson, MD, PhD, FACC, FAHA
Racial and Gender Disparities in CVD - Karol E. Watson, MD, PhD, FACC, FAHA
Advances in LDL-C Reduction: Implications for Treatment and Safety - Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Residual Cardiovascular Risk Reduction - Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Clinical Cases - Moderated by Karol E. Watson, MD, PhD, FACC, FAHA

Activity Chair

Karol E. Watson, MD, PhD, FACC, FAHA
Professor of Medicine/Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Co-Director, UCLA Program in Preventive Cardiology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

Faculty

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
Member
Louisiana Governor’s COVID-19 Health Equity Task Force
Louisiana Vaccine Action Collaborative (VAC)
New Orleans, LA

Disclosure: Consulting Fee: Alnylam, Amgen, Medtronic, Novartis


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC

Disclosure: Consulting Fee: Amgen, Esperion, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education and Association of Black Cardiologists Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Amarin Pharma Inc. and Esperion Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Association of Black Cardiologists continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and Association of Black Cardiologists. Neither Vindico Medical Education, Association of Black Cardiologists nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Paul Dorian, MD
1.00 CME / CNE / CPE
AcademicCME
Advances in Patient-Controlled On-Demand Treatment of Paroxysmal Supraventricular Tachycardia

Advances in Patient-Controlled On-Demand Treatment of Paroxysmal Supraventricular Tachycardia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 CNE Contact Hour(s)
1.0 CPE Contact Hour(s) (CEUs)
Released: June 3, 2021
Expires: June 2, 2022
60 minutes to complete

Accredited By

Target Audience

The target audience includes interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians who manage patients with PSVT.

Learning Objectives

  1. Review the symptom burden, epidemiologic, and pharmacoeconomic basis of current abortive strategies for PSVT
  2. Analyze and understand the different perspectives of various healthcare providers on optimizing PSVT management
  3. Discuss workflow, collaboration, and management strategies for clinical trial execution in the current pandemic-impacted era of practice
  4. Review in detail the rationale and methodology of a Phase 3 clinical trial that identifies patients with PSVT suitable for patient-actuated treatment, and follow its execution as the scientific, clinical, and outcomes-driven environment of PSVT management evolves

Activity Description

Unpredictable episodes of paroxysmal supraventricular tachycardia (PSVT) often have a negative impact on patient quality of life by causing uncomfortable, disconcerting symptoms during episodes (e.g., palpitations, chest pain, dizziness, syncope, shortness of breath, anxiety), by imposing restrictions on patient activities, and by potential association with medication-related side effects. Among commercially insured patients, healthcare spending increases substantially following diagnosis of PSVT, and more than two-thirds of that increased spending is for services related to PSVT and other cardiac rhythm disorders. These spending increases are seen for both outpatient and inpatient services; in particular, emergency department (ED) visits and hospitalizations both increase in the year following diagnosis, and then look-back analysis typically confirms that ED utilization is also high in the year prior to diagnosis, potentially reflecting difficulties with diagnosis. Current treatment approaches for PSVT are associated with a large burden on providers and carry a high economic burden for payers; just as importantly, however, they create a sense of powerlessness among many patients that often cannot be addressed with a reliable self-treatment strategy. New approaches are warranted to improve diagnosis, management, quality of life, and sense of well-being among patients with PSVT.

AcademicCME has developed a 1-hour program addressing the epidemiology, disease burden, definitive diagnosis, and current therapy of acute episodes of PSVT, along with information about an ongoing phase 3 trial that will evaluate the safety and efficacy of an on-demand, patient-actuated treatment for PSVT.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with paroxysmal supraventricular tachycardia (PSVT).

Agenda

  1. PSVT: Disease Burden
  2. Clinical Perspectives on Current and Emerging Pharmacologic Therapies for PSVT
    1. The NODE-301 and RAPID Phase 3 Trials
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a New, Patient-Actuated Therapy for PSVT
  4. Challenges in Executing Clinical Trials in the Acute Care Environment During COVID
  5. Expert Panel Discussion

Faculty

Paul Dorian, MD
Professor of Medicine and Pharmacology
University of Toronto
St Michael’s Hospital
Toronto, Ontario, Canada


Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Bruce Stambler, MD
Cardiology and Electrophysiology
Piedmont Heart Institute
Atlanta, Georgia

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; Milestone Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca Pharmaceuticals

Paul Dorian, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Bruce Stambler, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit(s)™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.

The Royal College and Physicians and Surgeons of Canada recognizes credits offered by the ACCME through the International Academy for CPD Accreditation agreement.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-21-013-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
    • CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    • CME and CNE credit will be issued appropriate certificate of completion.
    • Others may request a "certificate of completion".
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Milestone Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Milestone Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 CNE Contact Hour(s)
1.0 CPE Contact Hour(s) (CEUs)
Released: June 3, 2021
Expires: June 2, 2022
60 minutes to complete

Accredited By

Target Audience

The target audience includes interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians who manage patients with PSVT.

Learning Objectives

  1. Review the symptom burden, epidemiologic, and pharmacoeconomic basis of current abortive strategies for PSVT
  2. Analyze and understand the different perspectives of various healthcare providers on optimizing PSVT management
  3. Discuss workflow, collaboration, and management strategies for clinical trial execution in the current pandemic-impacted era of practice
  4. Review in detail the rationale and methodology of a Phase 3 clinical trial that identifies patients with PSVT suitable for patient-actuated treatment, and follow its execution as the scientific, clinical, and outcomes-driven environment of PSVT management evolves

Activity Description

Unpredictable episodes of paroxysmal supraventricular tachycardia (PSVT) often have a negative impact on patient quality of life by causing uncomfortable, disconcerting symptoms during episodes (e.g., palpitations, chest pain, dizziness, syncope, shortness of breath, anxiety), by imposing restrictions on patient activities, and by potential association with medication-related side effects. Among commercially insured patients, healthcare spending increases substantially following diagnosis of PSVT, and more than two-thirds of that increased spending is for services related to PSVT and other cardiac rhythm disorders. These spending increases are seen for both outpatient and inpatient services; in particular, emergency department (ED) visits and hospitalizations both increase in the year following diagnosis, and then look-back analysis typically confirms that ED utilization is also high in the year prior to diagnosis, potentially reflecting difficulties with diagnosis. Current treatment approaches for PSVT are associated with a large burden on providers and carry a high economic burden for payers; just as importantly, however, they create a sense of powerlessness among many patients that often cannot be addressed with a reliable self-treatment strategy. New approaches are warranted to improve diagnosis, management, quality of life, and sense of well-being among patients with PSVT.

AcademicCME has developed a 1-hour program addressing the epidemiology, disease burden, definitive diagnosis, and current therapy of acute episodes of PSVT, along with information about an ongoing phase 3 trial that will evaluate the safety and efficacy of an on-demand, patient-actuated treatment for PSVT.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with paroxysmal supraventricular tachycardia (PSVT).

Agenda

  1. PSVT: Disease Burden
  2. Clinical Perspectives on Current and Emerging Pharmacologic Therapies for PSVT
    1. The NODE-301 and RAPID Phase 3 Trials
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a New, Patient-Actuated Therapy for PSVT
  4. Challenges in Executing Clinical Trials in the Acute Care Environment During COVID
  5. Expert Panel Discussion

Faculty

Paul Dorian, MD
Professor of Medicine and Pharmacology
University of Toronto
St Michael’s Hospital
Toronto, Ontario, Canada


Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Bruce Stambler, MD
Cardiology and Electrophysiology
Piedmont Heart Institute
Atlanta, Georgia

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; Milestone Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca Pharmaceuticals

Paul Dorian, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Bruce Stambler, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit(s)™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.

The Royal College and Physicians and Surgeons of Canada recognizes credits offered by the ACCME through the International Academy for CPD Accreditation agreement.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-21-013-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
    • CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    • CME and CNE credit will be issued appropriate certificate of completion.
    • Others may request a "certificate of completion".
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Milestone Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Milestone Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.